Leukemia Clinical Trial
Official title:
Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)
The goal of this clinical research study is to learn if Vidaza (azacitidine) will help to control the disease in patients with AML, CMML, or MDS after an allogeneic (donor) stem cell transplant. The safety of this drug will also be studied.
The Study Drug:
Azacitidine is designed to block certain genes in cancer cells whose job is to stop the
function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes
may be able to work better.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned (as
in a flip of a coin) to 1 of 2 groups.
- If you are in Group 1, you will receive azacitidine.
- If you are in Group 2, you will not receive azacitidine.
Study Drug Administration:
If you are in Group 1, you will receive azacitidine through a needle under your skin on Days
1-5 of each cycle.
Each cycle is 28 days long.
Your dose of azacitidine may be lowered or stopped if certain side effects develop.
Study Visits:
About 2 or 3 days before each cycle and, if your doctor thinks it is needed, on Day 3 of each
cycle and 1 time during Weeks 2 and 3 of each cycle, blood (about 4 teaspoons each time) will
be drawn for routine tests.
At 3, 6, and 12 months after the stem cell transplant:
- You will have a complete medical history and physical exam.
- Blood (about 4 teaspoons each time) will be drawn for routine tests.
- You will have a bone marrow aspiration to check the status of the disease.
You may come back for study visits more often if the doctor thinks it is needed.
While on study, you will need to stay in Houston for about 3 months after the transplant
(this is standard after stem cell transplants).
Length of Study:
You will be on study treatment for up to 1 year (up to 12 cycles of azacitidine). You will be
taken off study early if you experience intolerable side effects or the disease gets worse.
End-of-Treatment Visit:
After you complete the planned treatment with azacitidine, you will have an end-of-treatment
visit:
- You will have a complete medical history and physical exam.
- Blood (about 4 teaspoons) will be drawn for routine tests.
- You will have a bone marrow aspiration to check the status of the disease.
This is an investigational study. Azacitidine is FDA approved and is commercially available
for the treatment of myelodysplastic syndrome.
Up to 246 patients will take part in this study. All will be enrolled at MD Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
| Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
| Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
| Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
| Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
| Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
| Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
| Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
| Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
| Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |